Theranos authorized new shares that would value the laboratory startup at over $10 billion, a filing shows, three days before The Wall Street Journal detailed the company’s struggles with its blood-testing technology.
from WSJ.com: US Business http://ift.tt/1HcMEDR
via IFTTT
No comments:
Post a Comment